CancerDrs

Lung Cancer (NSCLC, driver-mutation): drug payment transparency

Non-small cell lung cancer treatment is heavily stratified by driver mutation. For EGFR-mutant disease, first-line osimertinib is now standard but older-generation TKIs remain relevant. ALK-rearranged NSCLC has multiple first-line TKI options where head-to-head evidence is limited. Across settings, immunotherapy combinations involve multiple closely related checkpoint inhibitors.

Data from CMS Open Payments (2023–2024) · last checked

The drugs in question

These are the close-substitute branded therapies your oncologist may choose among for lung cancer (nsclc, driver-mutation). Generic and biosimilar options may also be available depending on line of therapy.

EGFR tyrosine kinase inhibitors

  • Tagrisso (osimertinib) — AstraZeneca
  • Tarceva / generic (erlotinib) — multiple
  • Gilotrif (afatinib) — Boehringer Ingelheim
  • Vizimpro (dacomitinib) — Pfizer

EGFR exon 20 insertion therapies

  • Rybrevant (amivantamab) — Johnson & Johnson

ALK inhibitors

  • Alecensa (alectinib) — Roche/Genentech
  • Alunbrig (brigatinib) — Takeda
  • Lorbrena (lorlatinib) — Pfizer

Immune checkpoint inhibitors (anti-PD-1 / PD-L1)

  • Keytruda (pembrolizumab) — Merck
  • Opdivo (nivolumab) — Bristol-Myers Squibb
  • Libtayo (cemiplimab) — Regeneron
  • Tecentriq (atezolizumab) — Roche/Genentech
  • Imfinzi (durvalumab) — AstraZeneca

Top paying manufacturers to oncologists in our index

Across all oncologists in our index (all cancer types), these are the companies making these lung cancer (nsclc, driver-mutation) drugs, summed across their latest reported year of disclosures. Payments include both general and research categories; see methodology for the split.

Manufacturer Total disclosed to oncologists (latest year)
AstraZeneca $11,913,894
Pfizer $8,033,132
Merck $5,435,449
Regeneron $3,712,458
Takeda $2,358,190
Genentech $1,699,825
Roche $1,694,787
Boehringer Ingelheim $449,059

lung cancer (nsclc, driver-mutation) trials with research-payment cross-reference

Active lung cancer (nsclc, driver-mutation) trials in our database where one or more research-payment records (tied to the trial's NCT ID) are disclosed in CMS Open Payments. We show the disclosed principal investigators and amounts. The presence of research payments on a trial is expected — industry-funded clinical trials pay the physicians running them for site work — but knowing the scale gives you useful context.

Questions to ask your oncologist

  • Among the approved options for my stage and biomarker profile, which do you recommend, and why this one over its close substitutes?
  • Have you received consulting, speaking, or research payments from the maker of the drug you're recommending? (Every U.S. physician can look themselves up at openpaymentsdata.cms.gov.)
  • Are there cooperative-group or NIH-sponsored trials I should consider, in addition to industry-sponsored ones?
  • What do the published head-to-head trials show for the option you're recommending versus its substitutes?

A financial relationship between a physician and a manufacturer is not, on its own, a problem — it is the expected context of modern drug development. The purpose of federal disclosure is to let you ask informed questions, not to make the decision for you.

More on lung cancer (nsclc, driver-mutation)

Lung Cancer (NSCLC, driver-mutation) overview

Staging, biomarkers, incidence and survival statistics.

Active trials

All recruiting lung cancer (nsclc, driver-mutation) trials nationwide.

Second opinion

How to get a second opinion for lung cancer (nsclc, driver-mutation).

Medical disclaimer: This page aggregates public federal data and is not medical advice. Drug choice for any individual patient depends on stage, biomarker profile, prior therapy, comorbidities, and patient preference — decisions that must be made with your licensed care team.

About the payment data: Figures are disclosed by manufacturers to CMS under the Physician Payments Sunshine Act (42 U.S.C. §1320a-7h). Presence of payments is not a conflict of interest. Physicians who believe a record is wrong file a correction through the CMS dispute process.

Sources: CMS Open Payments · ClinicalTrials.gov · Data fetched: 2026-04-21 · full methodology